GlassScriptPhysician profile
Alayna Vanwinkle
NPI 1598461428
$6,761.94
in general payments reported to CMS, 2019-2025
41 companies · $3,772 in 2025
The $3,772 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $52.79 · 2024: $2,937 · 2025: $3,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,761.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,056.54 | 2024-2025 | |
| Madrigal Pharmaceuticals | $717.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $615.15 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $596.85 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $482.55 | 2023-2025 | Repatha, Otezla, Repatha |
| Antares Pharma, INC. | $425.88 | 2024-2025 | Xyosted |
| Pfizer INC. | $316.40 | 2024-2025 | |
| Lundbeck LLC | $235.51 | 2024-2025 | Rexulti, Vyepti |
| Novartis Pharmaceuticals Corporation | $204.57 | 2024-2025 | |
| Lilly USA, LLC | $197.04 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Aimmune Therapeutics, INC. | $142.55 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.38 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $131.45 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $119.06 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $118.88 | 2024-2025 | Rexulti |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $114.34 | 2024-2025 | Veozah |
| Corcept Therapeutics | $114.30 | 2024-2025 | Korlym |
| Beta Bionics, INC. | $102.79 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $92.67 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $73.99 | 2024-2025 | Voquezna |
| Medtronic, INC. | $72.42 | 2024-2025 | Minimed 780g |
| Exact Sciences Corporation | $71.84 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.46 | 2025 | Caplyta |
| Cequr Corporation | $61.17 | 2024 | Cequr Simplicity |
| Verity Pharmaceuticals INC. | $51.89 | 2024-2025 | Tlando |
| Sumitomo Pharma America, INC. | $46.39 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.67 | 2025 | Jardiance |
| Currax Pharmaceuticals LLC | $42.88 | 2024-2025 | Contrave |
| Tolmar, INC. | $41.77 | 2024-2025 | Jatenzo |
| E.R. Squibb & Sons, L.L.C. | $41.48 | 2024-2025 | Eliquis |
| Abbott Laboratories | $37.34 | 2025 | Freestyle Libre 3, Proclaim |
| Edwards Lifesciences Corporation | $28.89 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Mannkind Corporation | $27.99 | 2024 | |
| Xeris Pharmaceuticals, INC. | $21.98 | 2024 | Recorlev |
| Boston Scientific Corporation | $18.04 | 2025 | Watchman Flx |
| Ironwood Pharmaceuticals, INC | $17.45 | 2024 | |
| Nalu Medical, INC. | $16.37 | 2025 | Nalu Neurostimulation System |
| Tempus Ai, INC | $16.18 | 2024 | Tempus Pixel |
| Ibsa Pharma INC. | $15.16 | 2024 | Tirosint, Licart |
| Seqirus USA INC | $13.24 | 2024 | Fluad, Flucelvax |
| Biowound Solutions, INC. | $7.01 | 2024 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alayna Vanwinkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.